Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus lenvatinib versus lenvatinib in advanced hepatocellular carcinoma after atezolizumab + bevacizumab
2025-524591-30-00Phase 2Authorised
- Sponsor
- Akeso, Inc.
- Start
- Sep 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Cadonilimab + lenvatinib with Lenvatinib (2 arms). Primary endpoint: Objective response rate. Planned start Sep 2026; status: authorised.
02
Drugs
cadonilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2025-524591-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524591-30-00.